Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation.
Brian A KellerBrian J LaightOliver VaretteAron BroomMarie-Ève WedgeBenjamin McSweeneyCatia CemeusJulia PetrykBryan LoBruce BurnsCarolyn NessimMichael OngRoberto A ChicaHarold L AtkinsJean-Simon DialloCarolina S IlkowJohn C BellPublished in: Journal of cancer research and clinical oncology (2021)
Our model of BRAFK601N-activated melanoma was developed, thoroughly characterized, and made available for public accession. This model served to demonstrate the feasibility of a novel personalized oncology platform that could be optimized at an institutional level for rare variant or treatment-refractory cancers. We also demonstrate the clinical utility of monotherapy MEK inhibition in a case of BRAFK601N melanoma.